The Long-Term Effects of Low Level Laser Therapy (LLLT) Combined with Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study by Bramlett, Olivia et al.
City University of New York (CUNY) 
CUNY Academic Works 
All Dissertations, Theses, and Capstone 
Projects Dissertations, Theses, and Capstone Projects 
6-2014 
The Long-Term Effects of Low Level Laser Therapy (LLLT) 
Combined with Complex Decongestive Therapy (CDT) in the 
Treatment of Breast Cancer Lymphedema: A Double-Blind, 
Randomized, Placebo-Controlled Study 
Olivia Bramlett 
Graduate Center, City University of New York 
Igor Daysudov 
Graduate Center, City University of New York 
Toshi Odaira 
Graduate Center, City University of New York 
Bethany Rodriguez 
Graduate Center, City University of New York 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/gc_etds/798 
Discover additional works at: https://academicworks.cuny.edu 












The Long-term Effects of Low Level Laser Therapy (LLLT) combined with 
Complex Decongestive Therapy (CDT) in the treatment of Breast Cancer 

































A capstone project submitted to the Graduate Faculty in Physical Therapy in partial 
fulfillment of the requirements for the degree of Doctor of Physical Therapy, The City 















This manuscript has been read and accepted for the Graduate Faculty in Physical 

























Date: Dr. Jeffrey Rothman 
Professor and Chair  
Department of Physical Therapy  



















The Long-term Effects of Low Level Laser Therapy (LLLT) combined with 
Complex Decongestive Therapy (CDT) in the treatment of Breast Cancer 











Adviser: Professor Susan Pivko PT, Cert. MDT, Adv. CIECP, Cert. FDM 
 
 
Complex Decongestive Therapy (CDT), the gold standard for lymphedema 
treatment, fails to demonstrate long-term efficacy.  The purpose of this study was to 
determine the long-term efficacy of low level laser therapy (LLLT) in reducing post-
mastectomy lymphedema when used with CDT. The experimental group received 
LLLT and CDT (n = 7) while control group received sham laser and CDT (n = 7), 
twice a week for 4 to 8 weeks.  Percent arm circumference difference between 
affected and unaffected limbs was collected over 18 months.  Results revealed no 
statistical difference between both groups at all time periods: 1 (p = 0.902), 2 (p = 
0.535), 3 (p = 0.445), 6 (p = 0.095), 12 (p = 0.537) and 18 months (p = 0.4).  Further 
study with a larger sample size may prove more significant for long-term efficacy of 
LLLT. 
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Cancer is a major public health issue in the United States and the rest of the 
world. Currently, cancer accounts for 25% of all mortality in the United States (Siegel, 
Ward, Brawley, & Jemal, 2011).  Among women, the cancers of the lung, bronchi, 
colorectal and breast are leading causes of cancer deaths.  Breast cancer is the second 
leading cause of cancer death among women, with approximately 232,600 new cases 
expected for 2011 and an estimated 39,500 deaths (Siegel et al., 2011).  Although there 
has been a decline in incidence of breast cancer reports since 1998, the decline in rate 
since 2003 has become stagnant (Siegel et al., 2011).  
Treatment for breast cancer is complex.  It entails a high risk of causing the onset 
of lymphedema, which is considered the most dreaded, secondary pathology related to 
breast cancer treatment (Fu, Ridner, & Armer, 2009).  Lymphedema is swelling and 
chronic inflammation that develops in the limb as a result of abnormal accumulation of 
tissue proteins and interstitial fluid (Brennan, DePompolo, & Garden, 1996).  Abnormal 
accumulation of lymph fluid mostly occurs in the interstitial spaces of the arm, shoulder, 
neck, breast or the thorax, which can lead to physical discomfort, pain, impaired function 
and emotional distress (Fu et al., 2009).  Of the approximately three to five million 
patients in United States who suffer from lymphedema, a significant proportion have 
developed lymphedema as a result of breast cancer treatment (Lawenda, Mondry, & 
Johnstone, 2009).  
The lymphatic system plays a critical role in maintaining homeostasis in the 
body.  It is a system that is responsible for ridding tissues of metabolic waste, foreign 
debris and excess materials by carrying them away from the tissues to the lymph nodes 
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via circulation of lymph fluid (Mortimer, 1998).  The lymphatic system is composed of 
deep and superficial lymph vessels, as well as lymph nodes, which are filled with lymph 
fluid (Cohen, Payne, & Tunke, 2001).  Lymph fluid consists primarily of protein, water, 
fatty acids, salts, white blood cells, micro-organisms and foreign debris (Lawenda et al., 
2009).  Excess protein, interstitial fluid or toxic foreign debris present in the skin and 
subcutaneous tissues are absorbed into lymph fluid and collected through the superficial 
lymphatic system (Lawenda et al., 2009).  The deep system is responsible for collecting 
lymph fluid in the deeper tissues (Lawenda et al., 2009).  Once waste and excess 
metabolic substances are collected, lymph fluid flows from lymph capillaries into the 
lymph nodes in the axillary and inguinal regions.  Lymph nodes then transport the fluid to 
lymphatic trunks, which will then drain lymph directly into the venous system for either 
disposal of waste or reabsorption of proteins (Lawenda et al., 2009).  
The lymphatic system also plays a major role in reduction and prevention of 
infection.  In addition to collecting excess interstitial water and proteins, the system can 
pick up bacteria and other foreign antigens and transport them to lymphocytes in the 
lymph node for processing (Cohen et al., 2001).  In a normal physiological state, the 
lymphatic system maintains a transport capacity that exceeds the volume of lymph fluid 
needed for transportation.  Lymphedema can be triggered due to either overload of 
lymphatic fluid or dysfunction of the lymphatic vessels that decrease the transport 
capacity (Lawenda et al., 2009). 
Lymphedema can be classified into primary and secondary lymphedema.  Primary 
lymphedema refers to congenital impairment of the lymphatic system (Fu et al., 2009; 
Brennan et al., 1996).  Secondary lymphedema can result from trauma such as cancer, 
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cancer treatment, infection, inflammation, chronic venous insufficiency, immobility, 
radiation or surgery (Fu et al., 2009; Brennan et al., 1996; Lawenda et al., 
2009).  Lymphedema triggered by breast cancer treatment is classified as secondary 
lymphedema.  
 First described as a side effect of mastectomy operations by William Halstead in 
1921, secondary lymphedema related to breast cancer can be caused directly by the tumor 
on the lymphatic vessels or more recently from indirect side effects of anti-cancer 
therapies (Mortimer, 1998; Brennan et al., 1996).  Significant impairment of lymphatic 
function can occur when lymphatic structures are injured and replaced with fibrotic tissue 
as a result of resection of nodes and radiation therapy that are conducted as part of cancer 
treatment (Brennan et al., 1996).  Lymphedema occurs more frequently in breast cancer 
patients who receive both resection of lymph nodes and radiation therapy.  The incidence 
can be up to 23% for patients receiving a combination of sentinel lymph node biopsy 
(SLNB) and radiation therapy, and up to 48% for patients receiving axillary lymph node 
dissection (ALND) and radiation therapy (Lawenda et al., 2009).  
Lymphedema can be classified into four stages according to skin condition and 
degree of swelling (Fu et al., 2009).  Stage 0 is latent or sub-clinical lymphedema, with 
no visible edema but with possible, minor heaviness in the limb.  Stage 1 is considered 
reversible but exhibits visible edema, while stage 2 is considered non-reversible and 
displays visible edema with added characteristics of pitting and fibrosis of the 
skin.  Stage 3 exhibits pitting edema in a largely affected area of the limb, as well as 
fibrosis and leakage of lymph through damaged skin (Fu et al., 2009).  Stage 3 is 
considered severe but rare in upper extremity lymphedema (Fu et al., 2009).  
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The signs and symptoms of lymphedema are readily visible, significantly altering 
not only the physique but also the self-perceived image of one’s physical 
presentation.  Lymphedema can have significant negative effects on wellness and on 
one’s ability to perform activities of daily living.  Range of motion of the wrist, hand and 
arm are affected by the inability of muscles and joints to move freely as a result of 
progressive stiffening of swollen superficial and deep tissues (Casley-Smith, Boris, 
Weindorf, & Lasinski, 1998).  Lymphedema can be accompanied by other distressing 
symptoms such as pain, fatigue, decreased physical activity, loss of sensation of the limb, 
diminished body image and other psychological distress associated with physical 
disfigurement caused by this substantial swelling (Fu et al., 2009; Lawenda et al., 2009; 
Cohen et al., 2001).  Often individuals socially isolate themselves secondary to physical 
presentation of edema and bandaging.  Currently there is no cure for lymphedema, but 
intervention is essential to delay onset and to eliminate further progression of the 
symptoms (Lawenda et al., 2009). 
 Physical therapy has been traditionally used for intervention of lymphedema since 
the techniques of “lymphatic massage” were first introduced in the 1930s (Casley-Smith 
et al., 1998).  Currently the gold standard for treatment of lymphedema is Complex 
Decongestive Therapy (CDT).  In one study, 35 patients with post-mastectomy 
lymphedema who underwent CDT reported a 25% decrease in percent excess volume in 
the affected limb when compared to the unaffected limb (Randheer, Kadambari, 
Srinivasan, Bhuyaneswari, Bhanumathy, & Salaja, 2011).  This study recruited subjects 
following the completion of breast cancer treatment with a 4-month onset of 
lymphedema.  Inclusion criteria required patients to have a difference in limb volume 
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between the two arms greater than 200 ml and a difference in one point of circumference 
of the two arms greater than 2 cm.  In addition, participants must have been free from 
reoccurring carcinoma, metastasis, cellulitis or from edema resulting from other medical 
causes (Randheer et al., 2011).  Parameters of interest were baseline circumference 
measurements of the upper limbs and water displacement volumetry (Randheer et al., 
2011).  Following the initial measurement, patients underwent CDT comprised of a 45 
minute session of manual lymphatic drainage and multi-layered compression bandaging 
for the duration of four times a weeks for 2 weeks.  Patients were also instructed to 
conduct massages on their affected limbs twice a day, apply compression bandages 
throughout the day and to elevate the limb at night.  After the 2 week CDT phase, 
patients were followed up once a month for three months for assessment of limb volume 
changes (Randheer et al., 2011).  Effectiveness of CDT was calculated as the change in 
absolute limb volume of the treated limb before and after the two-week phase and at each 
month of follow up.  The volume was also measured by calculating the difference in limb 
volume between the affected and unaffected limb and expressing it in percentage 
reduction of edema (Randheer et al., 2011).   
 
 
CDT is comprised of the following components: 
Manual Lymphatic Drainage (MLD): 
Manual Lymphatic Drainage is a technique that mobilizes excess lymph fluid in 
the extremities back into the body’s central lymph system to be removed.  It can be 
effective in decreasing edema, increasing range of motion of the limb, improving texture, 





 Based on individual needs, participants will receive a compression sleeve and 
gauntlet/glove that are to be worn in the daytime during the self-management phase in 
order to maintain the improvements made during intensive intervention (Casley-Smith et 
al., 1998). 
Multilayer Bandaging (MLB): 
  Multiple layers of short stretch elastic bandages are applied to the 
lymphedematous limb.  The tension of the bandages facilitates muscle pumping in order 
to push the accumulated lymph fluid back into the body’s central lymphatic system.  As 
with MLD, MLB has been proven to improve the range of motion of the limb, soften 
tissue texture, increase circulation and decrease risk of cellulitis (Casley-Smith et al., 
1998).  
Vasopneumatic compression: 
This may be used as an adjunct to treatment including MLD, MLB, and 
therapeutic exercise.  The compression device provides an automated sequence of 
gradient compression to the limb with lymphedema.  When compression is applied, it 
exerts gentle, external pressure on the affected extremity in order to rid edema by 
mechanically pumping the excess lymph fluid back into the center of the body (Casley-







Therapeutic exercises prescribed by the physical therapist promote active 
participation by the patient, in order to enhance muscle pump action to decrease the 
edema in the limb (Casley-Smith et al., 1998).  
Education: 
 Physical therapists educate the patients on posture, body mechanics, skin care and 
lymphedema precautions, such as avoiding venupuncture and vital readings (blood 
pressure) on the affected side.  Education is crucial in order to optimize activities of daily 
living and minimize risk of infection and exacerbation of lymphedema (Casley-Smith et 
al., 1998).  
Self-management: 
 When maximum improvements in girth measurement reduction and tissue 
softening have been achieved, the patient is provided with a self-managed plan of care 
upon discharge.  This may include a combination of compression garments, MLD (self-
administered), MLB (self-administered), exercise, and a vasopneumatic compression 
device (Casley-Smith et al., 1998). 
Despite the empirical support of CDT, there are numerous contraindications 
associated with CDT.  Complex decongestive therapy can increase venous blood volume 
in patients with hypertension and increase risk of injury or infection in diabetic patients 
with decreased tactile sensation (Fu et al., 1996).  Some absolute contraindications for 
CDT are acute infections, congestive heart failure, and deep vein thrombosis.  The 
compression involved in CDT may exacerbate infections, increase central venous blood 
volume in individuals with heart failure, and release clots in the blood vessel (Lawenda et 
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al., 2009).  Use of CDT for patients with these afflictions is contraindicated.  For such 
patients not suitable to be treated with CDT, it is necessary to develop an alternative 
mode of intervention. 
Low-level laser therapy (LLLT) is a physical modality with potential for a wide 
application of clinical use.  It has been used to relieve common symptoms ranging from 
stiffness and pain related to Achilles tendonitis, low back pain, orofacial pain, tendonitis, 
neck pain, temporomandibular pain, chronic periodontis and subacromial impingement 
syndrome (Yeldan, Cetin, & Ozdincler, 2009; Carcia, Martin, Houck, & Wukich, 2010; 
Djavid, Mehrdad, Ghasemi, Hasan-Zadeh, Sotoodeh-Manesh, & Pouryghoub, 
2007).  Low-level laser therapy has also been studied for its efficacy in reducing swelling 
and pain related to surgical removal of the third molar, commonly referred to as “wisdom 
tooth” (Ferrante et al., 2012).  
Historically both in vitro and in vivo studies have been conducted that aimed to 
study the efficacy and the mechanism of low-level laser (LLL).  The focus of many in 
vitro studies using the LLL has been on the effect of laser irradiation on the growth and 
repairing capacity of cells involved in wound healing and decreased formation of scarring 
(Posten et al., 2005; Omar, Ebid, & Morsy, 2011).  Most of such studies have focused on 
fibroblast growth, locomotion, and production of collagen, as fibroblasts play a 
significant role during the proliferative and remodeling phases of wound healing (Posten 
et al., 2005).  In addition, effects of LLL on monocytes and endothelial cells have also 
been studied.  The overarching result of these studies has shown that LLL enhances 
deposition of collagen and proliferation of fibroblasts and monocytes (Posten et al., 
2005).  
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Effect of LLL on wound healing has also been investigated with in vivo 
experiments using rodents as an animal model.  One earlier study used a Helium-Neon 
(HeNe) laser at 632.8 nm at a dose between 4 to 20 J/cm2 on surgical wound sites created 
in rat models to observe wound healing differences between different doses (Kana, 
Hutschenreiter, Jaina, & Waidelich, 1981).  The authors observed wound healing at a 
much more significant rate with application of 4 J/cm2 and also found that the lasers 
increased formation of granulation tissue and deposition of collagen (Kana et al., 1981).   
In addition to fibroblast activity during wound healing, many past animal studies 
have also investigated the effect of LLL on tissue tensile strength, vascularization around 
fractured bones, and wound healing around nerves (Posten et al., 2005).  Low-level laser 
therapy continues to stimulate the immune system by increasing prostaglandin levels, 
reducing edema, improving lymphatic drainage motility by vasodilatation and inhibition 
of platelet aggregation, and improving cellular growth for wound healing in human 
subjects (Omar et al., 2011).  
Historically, the therapeutic use of LLL can be traced back to a series of human 
studies conducted by Mester et al. beginning in 1971, that exhibited improvement in 
wound healing in chronic ulcers and neuropathic foot ulcers with application of low 
energy (1 J/cm3) laser (Mester, Spiry, Szende, & Tota, 1971).  Studies on the role of 
LLLT in wound healing were eventually applied to and used in treating secondary 
lymphedema.  The U.S. Food and Drug Administration (FDA) recommended that the 
dose for lymphedema treatment with laser was indicated to be 650 – 1000 nm in 2013 
(Ridner, Poage-Hooper, Kanar, Doersam, Bond, & Dietrich, 2013).  
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Currently, LLL has also been focused as an effective intervention in the treatment 
of post-mastectomy lymphedema (Carati, Anderson, Gannon, & Piller, 2003).  Approved 
by the FDA in November 2006, LLLT is a relatively new form of lymphedema treatment 
that utilizes light to stimulate healing response (Anderson, Pillar, Gannon, Carati & 
Angel, 2008).  It has been suggested that LLL enhances lymphangiogenesis (the growth 
of lymphathic vessels) and stimulates macrophage cells and breaks down fibrous tissue 
(Tammela, & Alitalo, 2010; Carati et al., 2003).  
One double-blind controlled trial was conducted that investigated the effect of 
LLL on post-mastectomy lymphedema in 11 women with unilateral lymphedema 
(Kaviani, Fateh, Nooraie, Alinagi-zadeh, & Ataie-Fashtami, 2006).  The subjects were 
randomly assigned to either the sham laser or laser treatment group and received laser 
application in the affected arm and axillary area three times a week for 3 weeks, followed 
by an 8 week interval.  Laser application was repeated for three more weeks after the 8 
week interval, for a total of 18 treatment sessions.  The laser used was a low-energy 
gallium arsenide laser at 890nm for a dose of 1.5J/cm2 (Kaviani et al., 2006).  The 
baseline assessment of limb circumference, range of motion, pain score and heaviness of 
the affected limb were compared between the two groups during the treatment period at 
3, 8, 12, 18 and 22 weeks.  Data were collected regarding the difference in circumference 
of the affected and unaffected limb and was measured using a non-elastic tape measure at 
6 specific anatomical points.  The circumference difference of the two limbs was 
compared to the circumference difference at pre-treatment sessions in order to calculate 
the total reduction in circumference (Kaviani et al., 2006).  The total reduction in 
circumference and the reduction in fluid as measured with the L-Dex scores of 
 11 
bioimpedence in the treatment group was significantly more than in the sham group in all 
sessions (p <0.001) (Kaviani et al., 2006).  In addition, pain significantly decreased in the 
treatment group in all sessions compared to the sham group with the exception of week 3 
and 9 (p <0.001) (Kaviani et al., 2006).  There was no significant difference in range of 
motion and in heaviness score between the treatment and sham groups.  The study does 
not depict the components of the heaviness and pain score, nor does it explain at which 
joints range of motion was studied. 
Another study on human subjects conducted a similar double-blind, placebo 
controlled trial to investigate the effect of LLL on limb volume, shoulder mobility and 
handgrip strength in women with post-mastectomy lymphedema (Omar, Ebid & Morsy, 
2011).  The study recruited 50 participants, all with unilateral lymphedema who qualified 
under the protocol and were assigned to either sham laser group or active laser 
group.  Low-energy gallium arsenide laser at 904nm, power of 5mW and spot size of 
0.2cm2, at a final dose of 1.5J/cm2 was applied over the arm and axilla three times a week 
for 12 weeks (Omar et. al., 2011).  Total reduction of circumference, shoulder mobility 
measured as shoulder range of motion in flexion, abduction and external rotation; grip 
strength measured using a hand dynamometer were assessed at baseline prior to treatment 
(week 0) and at every 4 weeks during the 12 week treatment period (week 4, 8, 12) 
(Kaviani et al., 2006).  The total reduction in limb circumference was significantly 
greater in the treatment group than in the sham group at all assessed sessions (Kaviani et 
al., 2006).  Shoulder flexion and abduction significantly increased during week 8 and 12 
in the treatment group, but there was no significant difference in external rotation 
between the two groups during any session (Kaviani et al., 2006).  Grip strength 
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improved in both groups, but the laser group exhibited significant percentage of 
improvement at week 12 compared with the sham group (Kaviani et al., 2006). 
Need for Study 
Several double blind, placebo-controlled studies have been conducted to 
investigate the efficacy of LLL on treating post-mastectomy lymphedema.  However, 
most studies follow up on the efficacy of LLL application for less than a year.  The 
interest of this research was to investigate the long lasting effect of LLL application in 
preventing recurrence of lymphedema, if any, by following subjects over time after active 
treatments have ceased.  In addition, most studies do not assess LLL in conjunction with 
the use of CDT.  For patients already receiving CDT, it is worthwhile to know if the 
further addition of LLL intervention would have any positive impact on treatment 
outcome.   
LLL has several parameters that must be defined clearly in each study, at times 
complicating meaningful comparisons of results between studies.  Low-level laser has 5 
defining factors: power, wavelength, pulse rate, pulse duration, total irradiation time, 
intensity and dose (Posten et al, 2005).  Low-level laser is defined to have a power with a 
range between 10-3 and 10-1 W, wavelength with a range between 300 and 10,600nm, 
pulse rate with a range between 0 and 5,000 Hz, pulse duration with a range between 1 to 
500 milliseconds, total irradiation time between 10 to 3,000 sec, intensity between 10-2 to 
100 W/cm2, and a dose between 10-3 to 102 J/cm2 (Posten et al, 2005).  Although the overall 
effects of LLL seem to be positive, there is no agreement on the most optimal 
physiological and physical parameters of the use of LLL that yield the best clinical 
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outcome (Kaviani et al., 2006).  Further studies are necessary to help define the exact 
parameter of LLL that is most optimal for clinical use in treating lymphedema.  
Longitudinal data supporting CDT efficacy is limited and lends to poor carry over 
when compared to more conservative treatment like compression stockings.  One recent 
study revealed no significant difference between percent arm reduction volume at all time 
period: 3, 6, 12, and 24 weeks between a control group which donned a compression 
sleeve 12 waking hours for 4 weeks and an experimental group which received CDT and 
MLD for 1 hr by a specialist 5 days per week for 4 weeks (Dayes, Whelan, Julian, Parpia, 
Pritchard, D’Souza, Kligman, Reise, LeBlanc, McNeely, Manchul, Wiernikowski, & 
Levine, 2013).  Each session followed with compression bandaging performed by a 
specialist to be worn for 23 hrs and each subject was taught self-bandaging to be used 
over the weekend.  After 4 weeks of the active phase was over, subjects of the 
experimental group received compression sleeves similar to that of the control group 
(Dayes et al., 2013).  Although still statistically insignificant, greater arm reduction was 
seen in subjects receiving CDT for the sub group with a shorter duration of onset (Dayes 
et al., 2013).  Greater duration (> 1 year versus < 1 year) may explain an increased risk of 
tissue fibrosis in a lymphedematous arm.  Manual Lymphatic Drainage in addition to 
compression stockings, may be effective.  Greatest arm volume reduction may occur over 
the first several weeks (approximately 3) (Dayes et al., 2013).  If there is no benefit to 
costly CDT, when compared to economical compression sleeves, conservative therapy 
may be indicated.  Complex Decongestive Therapy depends heavily on patient 
compliance and incorporates MLD, daily bandaging, exercise, and skin care.  During the 
maintenance phase (long-term post treatment phase), the individual is responsible for 
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compression bandaging, exercise and skin care.  Subjects in both sham and active laser 
group may have had low rates of compliance, except for the benefits of LLLT 
outweighing any decrease in efficacy due to decreased individual compliance (Javid & 
Anderson, 2013). 
Purpose 
The purpose of this study is to determine if LLLT in conjunction with CDT can 
have a long-term effect in reducing post-mastectomy lymphedema in breast cancer 
survivors.  The implementation of LLL is quick, easy to administer, and non-invasive; 
while CDT is time consuming for patients and clinicians.  Efficacy of MLD and 
bandaging are also dependent on the skill level of the Clinical Lymphedema Specialist as 
well as the compliance and skill level of the patients.  In addition, proper technique of 
bandaging with the non-dominant upper extremity can be difficult when the 
lymphedatemous arm is the dominant hand.  If LLLT is effective, it allows for non-
specialized clinicians to be involved in the care of people with secondary lymphedema 
and is simpler to don for those whose dominant arm is affected (Ridner, Poage-Hooper, 
Kanar, Doersam, Bond, & Dietrich, 2013).  
Omar et al (2011) showed that there was significant improvement in reduction of 
limb volume in the lymphadematous arm up to 12 weeks post LLLT treatment, compared 
to a sham laser group in a double blind, randomized study.  Subjects in both groups 
received skin care, therapeutic exercises, compression bandaging but NOT MLD.  This 
study shows that rather than just a hypothesized in-direct effect of LLLT on MLD, LLLT 
alone does have good efficacy (Omar et. al., 2011).  
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One double-blind, placebo-controlled study revealed no significant correlation 
between the duration of lymphedema (2 – 336 months) and reduction of arm 
volume.  However, at three months, after two treatment bouts of LLLT (8 week rest 
period between two rounds of laser treatments), mean affected limb volume was 
significantly lower than that of placebo group or group receiving one bout of  LLLT (8 
week rest period between placebo and one round of laser treatment) (Carati, Anderson, 
Gannon, & Piller, 2003).  Research shows subjects who developed lymphedema in the 
leg post surgery for gynecological cancer showed the effectiveness of CDT reached the 
greatest reduction in Percentage Excess Volume (PEV) 3 and 6 months post CDT, but 
reduction became insignificant as edema returned to pre-CDT level (2 months and 24 
months) (Kim, Hwang, Kim, Chang and Lee, 2012).  Percent average limb reduction had 
been noted until 6 months, but did return to pre-trial level during assessment time period 
at long-term defined as 12 months and 18 months (Kim et al, 2012). Moreover, one study 
where subjects were divided into 2 groups –PEV < 20% (group 1) and PEV ≥ 20% 
(group 2) and received 2 weeks of CDT treatment followed by maintenance phase (self-
care) and data collected at 3, 6, 12 and 24 months; PEV in group 2 was significantly 
lower than baseline at all time periods, while PEV in group 1 began to increase at 6, 12, 
and 24 months (Hwang, Hwang, Kim, Lee, Chang & Chu, 2013).  Complex decongestive 
therapy has been shown to be less effective long-term with initial PEV < 20% (Hwang et. 
al., 2013).  
With regard to possible development of fibrosis as one of the complications of 
lymphedema, fibrotic tissue inhibits efficient MLD and fluid drainage.  Another study 
noted the tissue indentation resistance (TIR) by calculating the amount of force required 
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to indent tissue to a certain depth (Mayrovitz & Davey, 2011).  The LLL implemented by 
this research was produced by RianCorp LTU 904H – pulsed 904 nm, with an average 
output of 5 mw from head size 0.2cm2.  In addition, use of tonometry revealed significant 
reduction in indentation forces with 5 minutes of LLLT as compared to pre LLLT forces 
(Mayrovitz & Davey, 2011).  A study by Ramos et al. recruited 69 subjects and showed 
that rather than the timing of initiation of treatment, the biggest factor for efficacy 
appeared to be PEV at baseline (Ramos, O’Donnell, & Knight, 1999).  
When compared to LLLT, CDT has been criticized partly for high cost over a 
long-term period and for time consumption.  Complex Decongestive Therapy 
incorporates an average of 60 minutes of MLD, as well as highly involved individual 
participation during the maintenance phase that can yield decreased compliance 
(Lasinski, Thrift, Squire, Austin, Smith, Wanchai, Green, Stewart, Cormier, & Armer, 
2012).  Empirical research suggests the implementation of conservative treatment of a 
compression sleeve, pneumatic pump or LLL could be recommended (Haghighat, Lotfi-
Tokaldany, Maboudi, Bahadori, & Weiss, 2013; Dayes, et al., 2013). 
Currently no study examines the relationship between the use of LLLT and the 
possible recurrence of, or increased risk of, metastasis (Lima, Lima, Figueiredo, Carvalho 
de Andrade, & Bergman, 2012).  One in vitro study showed a down regulation of protein 
expression responsible for cell adhesion, which can be related to metastasis (Leeuwen, 
Dekker, Byers, Vermeer and Grevelink, 1996).   
In consideration of the importance of promoting public health and wellness, 
obesity (BMI > 30kg/m2) is a risk factor at reportedly three times greater risk for 
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developing lymphedema (Helyer, Varnic, Le, Leong, & McCready, 2010).  Although 
lymphedema risk is associated with numerous factors such as stage of cancer, age, type of 
surgery, adjunct treatment, BMI is an important predictor for development of 
lymphedema (Helyer et, al., 2010). 
Educating breast cancer patients to the importance of detection of lymphedema 
well into post-ALND is paramount since the average onset of post surgical lymphedema 
is 36 months and some research notes onset up to 2 years later (ALND = 20% vs. SLNB 
= 5.6%) (Liao, Li, Huang, Chen, Kuo, Chen, & Wei, 2013; Javid & Anderson, 
2013).  Teaching individuals to detect early onset of mild lymphedema is crucial as 
research shows approximately 20% of mild lymphedema progresses into more severe 
lymphedema in one year (Bar, Cheville, Solin, Dutta, Both, & Harris, 2010).  In addition, 
increase risk in lymphedema is associated with post-operative infection or delayed wound 
healing and LLLT may be implicated for management of infection control and wound 
management as 17-25% of breast cancer survivors are at risk for secondary lymphedema 
(Lima et. al., 2012). 
Hypothesis  
The implementation of low level laser therapy (LLLT), in conjunction with 
standard lymphedema intervention (CDT), can potentially decrease risk of infection, 
decrease arm girth measurement, reduce tissue fibrosis, and enhance tissue texture in the 






This study is a double-blind, randomized, control trial of breast cancer survivors 
with post-mastectomy lymphedema all receiving CDT.  Participants were randomized 
into a placebo group that received sham LLL application and a treatment group that 
received active LLL application. 
Subjects 
The venue of this study is Rusk Institute of Rehabilitation Medicine and NYU 
Clinical Cancer Center in New York, NY.  A total of 16 subjects were recruited, 7 of 
which were assigned to the placebo group, the other 7 assigned to the active laser group, 
and 2 who dropped out after the intensive phase.  Participants were recruited through 
informational flyers that were circulated at Rusk Institute of Rehabilitation Medicine, 
NYU Clinical Cancer Center and local community organizations (i.e. SHARE, Gilda’s 
Club) throughout the 5 boroughs of New York City.  Breast cancer survivors already 
receiving outpatient physical therapy for post-mastectomy lymphedema were invited for 
initial screening as a potential participant.  Patients interested in participating in the study 
proceeded through a referring physician or a nurse practitioner.  Signed hard copies of 
agreement of the participant’s inclusion into the study were obtained from both the 
participant and the referring physician prior to the participant’s inclusion.  All 
participants signed the consent form to participate in the study.  The NYU School of 
Medicine/NYU Langone Medical Center Institutional Review Board (IRB) and Human 
Research Protection Program (HRPP) committee and the Hunter College (HRPP)-IRB 
committee approved this research. 
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The following criteria were required for participant inclusion to the study: female 
of 21 years of age or older; affected by unilateral breast cancer which was treated by 
unilateral mastectomy (no prophylactic mastectomy); lymph node dissection surgery 
[sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection (ALND)]; 
affected with unilateral upper limb lymphedema; involved upper extremity fluid volume 
that is greater than or equal to 200 mL and/or a circumferential girth measurement of the 
affected limb at any 4 cm segment with a difference of 2 cm or greater in comparison to 
the unaffected contralateral upper extremity; stage I or stage II lymphedema; cognitively 
intact; and able to make the time commitment to participate in all treatment 
sessions.  Interpreters were assigned to all non-English speaking or limited English 
proficiency participants who met all inclusion criteria during each treatment session for 
the length of the study. 
Potential participants were excluded from the study based on the following: BMI 
> 40; active or metastatic cancer; currently or later undergoing adjuvant radiation or 
chemotherapy therapy; restrictive active range of motion interfering with the purposes of 
treatment; history of severe surgical disruption of arm; presence of primary or secondary 
lymphedema in the contralateral upper extremity; active renal failure; arterial 
insufficiency; congestive heart failure; chronic inflammatory conditions; use of a 
pacemaker; a past medical history of deep vein thrombosis (upper extremity); past use of 
CDT and/or LL; use of medication which alters fluid balance (i.e. diuretic, certain 
chemotherapy); pregnancy.  
Materials 




• The LTU-904 infrared laser manufactured by RianCorp (Marleston, South 
Australia) was used in this study at a wavelength of 904nm. 
• Perometer Type 350 S manufactured by Pero-System Messgeraete GmbH 
(Wuppertal, Germany) was used to calculate total limb volume.  
• A bio-impedance analyzer, the L-Dex XCA U400 manufactured by ImpediMed 
(Brisbane, Australia) was used to measure the extracellular fluid volume of 
affected and unaffected limbs. 
• The DF-50 BIA manufactured by ImpediMed and the InBody 230 Body 
Composition Analyzer manufactured by BioSpace (Seoul, Korea) were used to 
measure and calculate percent body fat and BMI of each participant. 
• The Lymphedema and Breast Cancer Symptom Experience Index was used to 
monitor changes in overall experience pertaining to lymphedema in each 
participant as adapted from the Lymphedema and Breast Cancer Questionnaire 
(LBCQ) (Armer, Radina, Porock & Culberston, 2003; Fu et al., 
2008).  Participants were asked to self-assess the following lymphedema 
symptoms: swelling, heaviness, breast swelling, firmness/tightness, numbness, 
tenderness, aching, stiffness, impaired limb mobility, seroma formation, and arm 
weakness. Presence of each symptom is expressed as either “yes” or “no” whether 
they currently or recently had experienced the symptoms.  Severity of each 
symptom is expressed in a scale of 1 (a little) to 4 (severe).  The type of symptom 
distress is expressed as temporal, situational/functional, or attributive.  
• The Short-Form Health Survey version 2 (SF-36v2) was used to assess physical 
and mental health outcomes in each participant by monitoring changes in disease 
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burden associated with lymphedema.  The SF-36v2 was developed by John E. 
Ware Jr., PhD, and co-licensed by Medical Outcomes Trust (Dartmouth, NH), 
Health Assessment Lab (Boston, MA), and QualityMetric Incorporated (Lincoln, 
RI).  It consists of 36 questions, each with five different magnitudes of 
responses.  An 8-scale profile is gathered with measures of functional health and 
well being, physical and mental health that is a psychometric summary and a 
health utility index that is based on various preferences.  A median reliability 
coefficient of greater than or equal to 0.8 was used to establish reliability and 
validity for each of the 8 scales (Hormes, Bryan, Lytle, Gross, Ahmed, Troxel & 
Schmitz, 2010; Ahmed, Prizmet, Lazovich, Schmidtz, & Folsom, 2008). 
Procedures 
Participants were recruited as described above.  All principle investigators except 
for Annika Ginsberg, unaffiliated Research Coordinator, and Dr. Tamara Bushnik, 
unaffiliated Reasearch Director, both at Rusk Institute of Rehabilitation Medicine, were 
blinded to the subject’s randomization and whether a participant was in a sham laser or 
an active laser group. 
A total of four low level lasers, two active and two placebos were prepared, each 
pre-calibrated before use.  The laser discrimination for sham and active laser were known 
only to two unaffiliated personnel: the Research Coordinator and the Director of 
Research of Rehabilitation Medicine at Rusk Institute.  Recruited participants were 
randomly designated to the next available slot in either Group 1 that received sham laser 
application and CDT or Group 2 that received active laser application and CDT.  Each 
participant received an individual identifier number for use in all documentation, as well 
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as a laser number.  Each of the four low level lasers were designated a number of 1 
through 4.  
The laser treatments were administered by one of the two co-principal 
investigators who were trained in using the LLL distributed along a fabric grid.  Each 
participant in both groups had a personalized grid to be consistently used throughout the 
study.  The grid was placed over the axillary region and medial-lateral chest wall of the 
involved upper quadrant implementing pre-determined anatomical landmarks to ensure 
consistency from treatment to treatment.  This grid was used to ensure consistent 
application of the LLL among treatments and in order to treat the entire area 
equally.  The grids were pre-cut with 40 punctured holes.  The holes were color coded 
into 4 groups: red, blue, green and black.  The holes alternated in color spaced ≥ 2 cm 
between consecutive same-colored holes.  The laser treatment followed a set of color-
coded holes rotating each treatment on a four-week cycle.  Systematic treatment of the 
involved area was provided by alternating the color-coded holes as follows: 
• LLL treatment 1, 5, 9, 13 (red holes) 
• LLL treatment 2, 6, 10, 14 (blue holes) 
• LLL treatment 3, 7, 11, 15 (green holes) 
• LLL treatment 4, 8, 12, 16 (black holes) 
In each treatment session, LLL was applied for 1 minute each at 10 locations in 
the axillary region of the lymphadematous arm as designated through the use of the 
standardized grid application.  Laser treatment sessions were scheduled twice a week for 
4 to 8 weeks, as part of the Intensive Phase, for a total of 8 to 16 treatment sessions.  The 
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duration of total weeks of treatment period was dependent on a timeline required to 
achieve clinical goals.  Each laser treatment session was followed by a CDT session.  
The effects of sham and active laser treatment in combination with CDT on the 
lymphadematous arm were investigated by conducting a time course measurement of the 
following parameters: limb circumference, total limb volume, total extra-cellular fluid 
volume in limb, tissue texture, percent body fat, BMI, pain intensity, symptom 
experience of lymphedema, perceived health outcome, photography of limbs and 
demographics/ medical information (2nd visit only).  Measurement of each parameter was 
taken at the 1st treatment session (baseline reading), at the 8th treatment session and at the 
final treatment session.  Following the last treatment, measurements were recorded at 3, 
6, 12 and 18-month intervals, as part of the Maintenance Phase.  See Appendix for 
description on parameters. 
Results 
This research used Average Percent Difference of Circumferences between 
affected and unaffected upper extremity (UE) as the main outcome measure. 
Circumference measure is the most relevant outcome measure for comparison to other 
research.  It is easy to measure and is the most relevant measure to those affected with 
lymphedema.  Landmarks for circumference measurements were the index finger, thumb, 
MCP joint, CMC joint, and wrist. Distance from wrist was calculated as 4 cm + 4i, where 
i is equal to the next 4cm interval number, for a total of 9 intervals; with longer limbs, 2 




1.  Percent difference of each landmark – an affected UE is compared to unaffected 
• Let R be circumference of a landmark on the right UE 
• Let L be circumference of a landmark on the left UE 
• If right UE is affected: (R-L)/L x 100% 
• If left UE is affected:  (L-R)/R x 100% 
2.  Average percent difference across landmarks of a participant for a given visit in time –  
an average of percent differences of landmarks in #1 above 
3.  Average percent difference of all landmarks for all participants in a sham or an active 
laser group for a given follow-up visit - #2 averaged across all participants for a given 
visit in time in a given participant group. 
Table 1  
Average % difference of all landmarks for all participants in a sham or an active 











1 1 10.86 7.85 7 7 
2 2 8.42 7.17 7 7 
3 3 9.06 6.38 6 7 
4 6 9.82 2.52 5 5 
5 12 9.38 6.79 5 6 







Figure 1  


























Results of Mann-Whitney U Test to determine significance of data distribution 
between laser vs. sham groups at each time period. 
Null Hypothesis Significance Decision 
The distribution of Month 1 is the same across 
categories of Group. 
0.902 Retain the null 
hypothesis. 
The distribution of Month 2 is the same across 
categories of Group. 
0.535 Retain the null 
hypothesis. 
The distribution of Month 3is the same across 
categories of Group. 
0.445 Retain the null 
hypothesis. 
The distribution of Month 6 is the same across 
categories of Group. 
0.095 Retain the null 
hypothesis. 
The distribution of Month 12 is the same across 
categories of Group. 
0.537 Retain the null 
hypothesis. 
The distribution of Month 18 is the same across 
categories of Group. 




According to Table 2, low significance in p-values suggests the results might have 
happened at random and that there is no significant difference between the two groups of 
participants.  However, using a regression analysis a better understanding of possible 
differences between the two groups of participants could be revealed.  Due to low 
significance values regression models are used for every group of participants and scatter 
plots gauge any trends in data. No attempt to extrapolate any data points was made. 
Data in Figure 1 indicates that there seemed to be a downward trend in the 
difference of average percent circumference between affected and unaffected UE over an 
18-month period for the participants who received an active laser treatment.  For this 
participant group linear regression model was used and revealed a reasonable data-trend 
representation with R2 = 0.5912.  This may suggest that lymphedema had a decreasing 
trend over the 18-month period for this participant group. 
However, data for a sham laser group fit into a parabolic regression model also 
having a reasonable data-trend representation with R2 = 0.6178.  Although statistically 
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insignificant, a decrease in average percent circumference was observed until 6 months, 
followed by an increase in average percent circumference for 12 and 18 months, as 
demonstrated by this parabolic trend.  This may suggest that initially participants in this 
group experienced a decreasing trend in lymphedema until about 6 months but then 
lymphedema continues to increase over the long term. 
Figure 2 
Effect of active vs. sham laser on limb circumference using raw measurements 





Although statistically insignificant, greatest percent average limb circumference 
difference in interquartile range and median were observed at 6 and 18 months between 
the sham and active laser treatment group (figure 2). 
Discussion 
The purpose of this study was to determine the long-term efficacy of LLLT in 
conjunction with CDT in reducing post-mastectomy lymphedema in breast cancer 
survivors.  Post-mastectomy lymphedema is a common complication, affecting 17 – 25% 
of patients who have undergone axillary lymph node dissection (Javid & Anderson, 2013; 
Lima et al., 2012).  Ever since “lymphatic massage” was first established in the 1930s, 
CDT has been the preferred treatment method for lymphedema (Casley-Smith et al., 
1998; Randheer et al., 2011).  However, Javid and Anderson (2013) reported that recent 
randomized trials have failed to confirm the efficacy of CDT over standard compression 
therapy.  The study by Dayes, Whelan, Julian, Parpia, Pritchard, D’Souza, Kligman, 
Reise, LeBlanc, McNeely, Manchul, Wiernikowski and Levine (2013) demonstrated that 
CDT had a poor long-term effect in reducing lymphedema.  In their study, control groups 
wore compression sleeves for 12 waking hours for 4 weeks, while the experimental group 
received MLD for 1 hour by a clinical lymphedema specialist for 5 days a week for 4 
weeks (Dayes et al., 2013).  Both groups received patient education on skin care, 
therapeutic exercise and body weight management during the follow up period. Results 
indicated no significant difference between percent arm volume reduction, quality of life 
measures and arm function measures at all periods of 3, 6, 12 and 24 weeks (Dayes et al., 
2013).  Many authors agree that the greatest reduction in arm volume after the use of 
CDT peaks in the first several weeks (Javid & Anderson, 2013).  
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Another purpose of this study was to examine the general efficacy of LLLT in 
reducing lymphedema post-mastectomy.  Efficacy of LLLT alone will facilitate clinical 
professionals who are not licensed to carry out MLD to be involved in lymphedema care. 
Opportunity exists for advanced practice nurse practitioners operating the low level lasers 
in areas with shortage of clinical lymphedema specialists (Ridner, Poage-Hopper, Kanar, 
Doersam, Bond, & Dietrich, 2013).  However, this research aimed  to determine  if 
LLLT, in conjunction with CDT, is still needed for long-term efficacy. 
The results of this study demonstrate a general trend toward a decrease in percent 
limb circumference difference over an 18 month period between the affected and 
unaffected limbs in the active laser group.  Despite the statistically insignificant 
difference between the two groups, the decreasing trend of percent limb circumference 
difference may indicate support for the alternative hypothesis that the use of LLLT in 
conjunction with CDT will decrease arm girth measurement in the involved upper 
extremity at 12 months when compared to sham LLLT with CDT.  The indirect effect of 
decrease in tissue fibrosis and direct effect of laser application may explain the arm 
volume reduction in the lymphadematous arm.  Work by Rufina, Lau and Cheing (2013) 
demonstrated that 4 weeks of LLLT on the axillary region decreased tissue fibrosis in the 
lymphadematous arm by 33%.  In the likelihood that our subjects had fibrotic tissue 
compositions in their lymphedematous arm, LLLT may have helped soften the fibrotic 
tissue to facilitate effectiveness of LLLT.  A study by Carati et al. (2003) demonstrated 
the efficacy of LLLT in a double-blind, placebo-controlled study. The study had three 
groups; a control group receiving only placebo laser treatment, an experimental group 
receiving one dose of LLLT, and another experimental group receiving two doses of 
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LLLT with an 8-week rest period in between the doses.  The results indicated no 
immediate reduction of arm volume after the laser treatment, but the experimental group 
receiving two doses of LLLT demonstrated significantly lower arm volume in the 
affected limb than the control or the other experimental group at the 3-month period.  
The results of our study also demonstrated an increasing trend in percent 
circumference difference over an 18-month period between the affected and unaffected 
limbs in the sham laser group receiving placebo laser treatment and conventional 
CDT.  The rather surprising result demonstrating the inefficacy of CDT over the 18-
month period may be explained by several factors.  
The total number of 17 subjects may have been too low to delineate any 
meaningful statistical significance to validate the finding of this study.  It is possible that 
use of CDT might have reduced the percent circumference difference between the 
affected and unaffected limb if the subject numbers were higher.  
Previous research has shown that the efficacy of CDT does not carry over past the 
6 month follow up period, causing the arm volume to return toward the baseline level.  It 
examined the percent excess volume (PEV) in affected limb compared to the unaffected 
limb in subjects who developed lymphedema in the lower extremity after surgical 
treatment for gynecological cancer (Kim, Hwang, Kim, Change & Lee, 2012).  It was 
found that the effectiveness of CDT reached the greatest reduction in PEV at 3 and 6-
month post CDT, but lymphedema returned to pre-trial level at 12 and 24 months. Our 
study findings were in congruence with findings by Kim et al. (2012) with average limb 
reduction observed until 6 months before returning to pre-trial level at 12 and 18 months.  
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Previous research has also demonstrated that CDT has decreased long-term 
effectiveness if initial PEV of subjects is less than 20%.  A study by Hwang et al. (2013) 
divided the treatment group into two sub groups; Group 1 composed of subjects with 
initial PEV less than 20% and Group 2 composed of subjects with PEV greater than 20%. 
Both groups received 2 weeks of CDT followed by a maintenance phase, during which 
difference in PEV was monitored over 24 months. Their study revealed that PEV in 
Group 2 was significantly lower than baseline at all time periods, while PEV in Group 1 
began to increase at 6, 12, and 24 months.  Our findings were in congruence with 
findings by Hwang et al. (2013), as the initial PEV for our subjects was recorded as 
10.86%.  
Possible development of fibrosis as one of the complications of lymphedema 
could have inhibited effectiveness of MLD in our study and subsequent fluid 
drainage.  Previous studies have demonstrated that 5 minutes of LLLT significantly 
reduced indentation forces in the lymphedematous arm, indicating possible effect of 
LLLT in decreasing soft tissue fibrosis (Mayrovitz & Davey, 2011).  To calculate fibrosis 
in skin, many authors use the tonometry method or measure the tissue indentation 
resistance by calculating the amount of force required to indent tissue to a certain depth 
(Mayrovitz & Davey, 2011).  Tissue texture assessment by palpation, tonometry, or 
calculation of tissue indentation force in future studies may reveal any presence of 
fibrosis in our subjects as well as any decrease in fibrosis when LLLT in conjunction 





Future studies could incorporate greater use of functional outcome measures as 
well as a focus on effect of lymphedema severity using LLLT as opposed to the use of 
standard compression sleeves.  Such studies could facilitate physical therapists and other 
clinicians in formulating rehabilitation goals and potentials for patients, knowing when to 
make appropriate referrals to other clinical disciplines dependent on lymphedema 
severity and having viable treatment alternatives for lymphedema patients inaccessible to 
LLLT due to financial or geographical reasons.  
Future studies could include functional outcome measures such as the Disability 
of the Arm, Shoulder and Hand (DASH) outcome measure to allow assessment of 
activities of daily living (ADL) affected by changes in physical function and symptoms 
caused by lymphedema.  In addition, future studies could measure combined upper 
extremity range of motion (ROM) of shoulder flexion, abduction, and external rotation to 
assess reaching tasks and self-care activities such as washing ones hair, as well as 
shoulder extension and internal rotation required for donning of undergarments.  Along 
with goniometric measurements of functional ROM, measurements of grip strength by 
hand dynamometry in functional positions may also assist physical therapists in 
monitoring patient progress and formulating treatment plans (Omar et al., 2011). 
Efficacy of LLLT against use of standard compression sleeves could be examined 
to assess if LLLT and compression sleeves are comparable in their efficacy in reducing 
lymphedema.  One criticism of CDT is its high cost, which often requires 60 minutes of 
MLD conducted by a certified lymphedema specialist (Lasinski et al., 2012).  If LLLT 
and compression sleeves demonstrate comparable efficacy, LLLT presents as another 
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viable treatment alternative for cost reduction and for patients with low compliance with 
which CDT would not be appropriate.  
Efficacy of LLLT on varying lymphedema severity and stages could be examined 
to explore if LLLT would be a good alternative over a CDT treatment strategy for 
patients with a greater PEV.  A study by Ramos, O’Donnell and Knight (1999) 
demonstrated that rather than the timing of treatment initiation, initial PEV at baseline is 
the most significant determining factor of treatment outcome. 
Future studies could also examine safety of the long-term use of LLL at currently 
established wavelengths.  Current recommended dose for lymphedema treatment 
determined by the U.S. Food and Drug Administration is 650 to 1000 nm  (Ridner et al., 
2013).  However, the possible correlation between long-term use of LLL at the indicated 
wavelength and increased risk of metastatic recurrence has not been studied (Lima et al., 
2012).  So far, an in vitro study conducted by Leeuwen, Dekker, Byers, Vermeer and 
Grevelink (1996) has shown that LLLT decreased expression of a protein that may be 
responsible for cell adhesions during metastasis. 
Aside from the obvious necessity of treatment advancement of lymphedema to 
promote patient return to pre-morbid level of activities, the importance of patient 
education on health and wellness must be advocated by all medical 
professionals.  Obesity, defined as body mass index (BMI) greater than 30 kg/m2, has 
been shown to increase the risk of developing lymphedema by threefold (Helyer, Varnic, 
Le, Leong & McCready, 2010).  Although cancer stages, age, type of surgery and adjunct 
treatment are considered to be associated risk factors to development of lymphedema, 
BMI is an important predictor for lymphedema (Helyer et al., 2010). 
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Patient education post-mastectomy is also crucial in preventing post-surgical 
complications and early detection of lymphedema.  Patients should be instructed to 
conduct frequent skin inspections to prevent delayed wound healing and post-operative 
infections, which are associated risk factors for development of lymphedema (Javid & 
Anderson, 2013).  A study conducted by Lao, Li, Huang, Chen, Kuo, Chen and Wei 
(2013) emphasizes the importance of patient education for early detection of 
lymphedema well into the post-ALND period, as average onset of lymphedema post-
ALND is 36 months.  In addition, early detection of seemingly mild lymphedema is 
critical, since 20% of mild lymphedema has been shown to progress into a more severe 
form of lymphedema within 1 year (Bar, Cheville, Solin, Dutta, Both & Harris, 2010).  
Conclusion 
Although there is not yet statistically significant evidence for the long-term 
efficacy of LLLT, the most recent literature along with our findings may suggest the 
following possibilities: Use of LLLT in conjunction with CDT may be indicated for long-
term management of lymphedema; Either CDT alone or LLLT with CDT may be 
effective in short term management of lymphedema up to 6 months post treatment; Use 
of LLLT may have a more significant effect post 6 months after the initiation of 
treatment. With continuation of the study and more subjects followed to 18 months, there 






Limb circumference and limb volume 
Protocol previously established by Armer, et al. (2004) and Armer and Stewart (2005); 
was used for circumference measurement for limb volume.  Circumference of both the 
affected and unaffected limbs was measured using a non-stretch tape at the following 
locations:  at the hand proximal to the metacarpals, wrist, and every 4 cm from the wrist 
to axilla (Callaway et al., 1988; Hutzschenreuter, Wittlinger, Wittlinger, & Kurz, 
1991).  Non-stretch tape was used to measure the circumference in order to ensure 
constant tension over soft tissue, muscle, and bony prominence, a flexible non-stretch 
tape measure was used for circumferential measurement (Callaway et al., 1988; Petlund, 
1991). Circumference of affected and unaffected limb was used to calculate the limb 
volume of each limb.  The following formula was used: V= ∑(X2 + Y2 + XY)/ 3π. V is the 
sum of the limb volume, X is the circumference at one point on the limb and Y is the 
circumference at a point 4 cm proximal to X. (Stantou et al., 1997). 
Total limb volume  
Total limb volume of affected and unaffected limb was measured using the Perometer 
350S.  Procedures for perometry as outlined by Armer & Stewart (2005); and as 
described by the equipment manual were followed.  The perometer generated a 3-
dimentional image of the limb to calculate the total limb volume.  There is a standard 






Total extra-cellular fluid volume in limb  
Extra-cellular fluid volume in the affected and unaffected limb was measured using the 
L-Dex XCA U400, a bio-impedance analyzer that measures resistance and impedance to 
calculate extracellular fluid volume.  The equipment manual provided by the 
manufacturer was followed for all procedures.  
Tissue texture 
A physical therapist palpated the affected and unaffected limb to compare and assess 
changes in skin compressibility.  Skin compressibility is indicative of the extent of 
fibrosis present in a limb (Piller & Thelander, 1998). 
Percent of Body Fat   
Percent of body fat was measured using the DF 50 BIA and InBody 230 Body 
Composition Analyzer.  This device sends an extremely weak electrical current of 50 kHz 
and less than 500 μA through the body to determine the amount of water in each tissue. 
Standard protocols established by each of the manufacturers were followed for all 
measurements.  Participants were requested to remove all jewelry and metal objects, 
before being positioned in stand and supine position.  The validity of using the BIA as the 
reference method ranged from 0.84–0.96 in white women (Pineau, Guihard-Costa, & 
Bocquet, 2007).  The reliability (ICC) of BIA ranged from 0.97–0.99 (Jackson et al., 
1988). 
Body Mass Index 
Body Mass Index was calculated by entering the body weight and height into the DF50 
BIA &InBody 230 device.  The device uses the following formula to calculate BMI 
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based on a ratio between body weight and height: BMI = weight (lb) / height (inches) 
/height (inches) x 703 (Callaway, Chumlea, & Bouchard, 1988).  
Pain intensity 
Pain intensity associated with lymphedema was measured using a self-reported, 
numeric pain scale. Participants quantified their pain on a numeric scale from zero to 
10.  A rating of zero signifies no pain while a rating of 10 signifies severely debilitating 
pain.  It is a validated scale and a standard tool for rating pain.  
Symptom experience of lymphedema  
The study used the Lymphedema and Breast Cancer Symptom Experience Index 
in order to monitor the participants’ overall experience of the lymphedema.  This index 
was a structured interview tool adapted from the Lymphedema and Breast Cancer 
Questionnaire (LBCQ) (Armer, Radina, Porock, & Culberston, 2003; Fu et al, 
2008).  The content of the Breast Cancer Symptom Experience Index is described under 
Materials.  
Perceived health outcome 
The Short-Form Health Survey version 2 [SF-36v2] was utilized to assess the 
well-being of physical and mental health of each participant. The content of the survey is 
described under Materials. 
Photography of limbs  
Photographs of the chest, affected and unaffected extremity were taken for each 
participant in order to monitor any visual changes over the upper quadrants of the body. 
Each subject was given the right to refuse the photo.  If photos were taken, they were 
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managed using the Individual Identifier Number. Photos were stored in a locked cabinet 
in a locked office of the Principal Investigator. 
Demographics and Medical Information 
A Demographics and Medical Information Tool as previously outlined by Fu, 
Axelrod and Haber (2008) was used to record the age, diagnosis, treatment, nodal status, 
numbers of lymph nodes removed, co-morbidities, and family medical history (breast 
cancer history, breast cancer gene status, morbidity of lower extremities).  
Throughout the 18 month study period, patients were instructed to report any 
adverse changes to their affected limb such as rash, blister, redness swelling and/or 
increased temperature of the tissue.  Participants were also instructed to receive any blood 
pressure evaluation, drawing of blood, injections and vaccinations on the unaffected 
upper limb whenever possible.   
At the end of the study, participants were contacted and informed about whether 
they were part of the placebo or an intervention group.  In the event that a medical 
problem arose, participants were instructed to contact Teresa Denham, PT, MA, Principal 
Investigator and Outpatient Physical Therapy Manager at New York University Medical 
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